GUILD Learning and Development is partnering with Gilead Sciences in an online course titled Management of Hepatitis C and the role of pharmacy.
Hepatitis C (HCV), a blood-borne virus which primarily affects the liver, is detectable in 0.9% of the Australian population, the Guild explained in its announcement.
Although there is no vaccine to prevent hepatitis C, advances in treatment of the condition have progressed significantly in the past couple of years with the broader availability of direct acting antiviral medications resulting in cure rates greater than 90%.
The Guild-Gilead course examines the pathophysiology of HCV and the availability of these new direct acting antivirals.
In addition, the course will also discuss the role pharmacists can play in supporting patients with chronic HCV through the provision of advice on screening, treatment, risk reduction and all-important treatment compliance.
This accredited activity is available through myCPD.org.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Aug 17
